#ThinkSabio Latest News
46% [Following the release of results from a clinical trial, Bicara Therapeutics’ stock price tumbled as the data for their drug candidate, ficerafusp alfa, showed mixed results.
LightDark
46% [Following the release of results from a clinical trial, Bicara Therapeutics’ stock price tumbled as the data for their drug candidate, ficerafusp alfa, showed mixed results.